Rübben H, Lutzeyer W
Urologe A. 1982 Jan;21(1):20-3.
Topical instillation of adriamycin for treatment of superficial bladder carcinomas is of little value (complete response less than 40%) in comparison to transurethral resection. Instillation therapy may be indicated in carcinoma in situ (objective response about 70%). Value of topical chemoprophylaxis is not proven in prospective randomized clinical studies up to now. Chemical cystitis is described as local side effect in about 40%, systemic side effects are not expected. Effectiveness of instillation therapy in BBN-induced tumors in the rat can be shown 2 and 8 weeks but not 5 month after the last instillation. Instillation therapy leeds to severe dysplasia and epithelial proliferation in the normal rat mucosa. Up to now topical instillation therapy with adriamycin is indicated in carcinoma in situ (therapeutic) and in multiple, recurrent or poorly differentiated T1 carcinomas (prophylactic).
与经尿道切除术相比，膀胱内灌注阿霉素治疗浅表性膀胱癌的价值不大（完全缓解率低于40%）。灌注疗法可能适用于原位癌（客观缓解率约为70%）。到目前为止，前瞻性随机临床研究尚未证实膀胱内化学预防的价值。约40%的患者出现化学性膀胱炎，这被描述为局部副作用，预计不会出现全身副作用。在最后一次灌注后2周和8周可显示灌注疗法对大鼠BBN诱导的肿瘤有效，但5个月后无效。灌注疗法会导致正常大鼠黏膜出现严重发育异常和上皮增生。到目前为止，阿霉素膀胱内灌注疗法适用于原位癌（治疗性）以及多发性、复发性或低分化T1期癌（预防性）。
